Syros Pharmaceuticals (SYRS) just unveiled an update.
Syros Pharmaceuticals presented promising yet cautious findings from their SELECT-AML-1 trial at the Society of Hematologic Oncology Annual Meeting. The trial studied the efficacy of tamibarotene in combination with venetoclax and azacitidine in treating adult patients with acute myeloid leukemia (AML) who have RARA overexpression and are ineligible for standard induction therapy. Early results show that while the combination was well-tolerated, it didn’t significantly improve response rates compared to the current standard treatment. However, there was some positive clinical activity with tamibarotene in patients who had relapsed, opening avenues for its potential use in improving long-term outcomes.
See more data about SYRS stock on TipRanks’ Stock Analysis page.
